Albireo Pharma, Inc. (NASDAQ:ALBO) CEO Sells $46,296.60 in Stock

Albireo Pharma, Inc. (NASDAQ:ALBO – Get Rating) CEO Ronald Harold Wilfred Cooper sold 1,057 shares of the firm’s stock in a transaction that occurred on Monday, January 23rd. The stock was sold at an average price of $43.80, for a total transaction of $46,296.60. Following the completion of the sale, the chief executive officer now owns 57,444 shares in the company, valued at approximately $2,516,047.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Albireo Pharma Trading Down 0.0 %

Shares of NASDAQ:ALBO traded down $0.01 during mid-day trading on Monday, reaching $43.80. 689,675 shares of the company traded hands, compared to its average volume of 892,105. Albireo Pharma, Inc. has a 52 week low of $16.02 and a 52 week high of $44.40. The company’s 50 day moving average price is $25.87 and its 200-day moving average price is $22.52.

Albireo Pharma (NASDAQ:ALBO – Get Rating) last announced its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported ($1.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.86) by ($0.03). The firm had revenue of $9.83 million during the quarter, compared to analysts’ expectations of $9.68 million. Albireo Pharma had a negative return on equity of 97.13% and a negative net margin of 228.51%. As a group, equities research analysts expect that Albireo Pharma, Inc. will post -7.86 EPS for the current year.

Institutional Investors Weigh In On Albireo Pharma

Institutional investors and hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC grew its position in shares of Albireo Pharma by 169.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,640 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 1,031 shares in the last quarter. Quadrant Capital Group LLC boosted its stake in Albireo Pharma by 4,397.4% in the 3rd quarter. Quadrant Capital Group LLC now owns 1,709 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 1,671 shares during the period. Barclays PLC grew its holdings in Albireo Pharma by 131.6% during the 3rd quarter. Barclays PLC now owns 2,003 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 1,138 shares in the last quarter. Lazard Asset Management LLC bought a new stake in shares of Albireo Pharma during the first quarter valued at approximately $75,000. Finally, US Bancorp DE raised its position in shares of Albireo Pharma by 38.4% during the second quarter. US Bancorp DE now owns 2,583 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 716 shares during the last quarter. 94.25% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ALBO. Guggenheim cut Albireo Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, January 11th. Wedbush cut Albireo Pharma from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $53.00 to $42.00 in a research report on Monday, January 9th. Cowen lowered shares of Albireo Pharma from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $68.00 to $48.00 in a research report on Wednesday, January 11th. HC Wainwright downgraded shares of Albireo Pharma from a “buy” rating to a “neutral” rating and set a $42.00 price objective on the stock. in a report on Tuesday, January 10th. Finally, Robert W. Baird boosted their target price on shares of Albireo Pharma from $43.00 to $55.00 and gave the company an “outperform” rating in a research report on Wednesday, October 12th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, Albireo Pharma presently has a consensus rating of “Hold” and an average price target of $48.00.

Albireo Pharma Company Profile

(Get Rating)

Albireo Pharma, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases.